Skip to content
Home » Celgene’s (CELG) CEO Robert Hugin on Q2 2014 Results – Earnings Call Transcript

Celgene’s (CELG) CEO Robert Hugin on Q2 2014 Results – Earnings Call Transcript

Source: Seeking Alpha

 

Celgene Corporation (NASDAQ:CELG)

Q2 2014 Earnings Conference Call

July 24, 2014 9:00 am ET

Executives

Robert Hugin – Chairman, Chief Executive Officer

Jacqualyn Fouse – Executive Vice President, Chief Financial Officer

Mark Alles – Global Head, Hematology and Oncology

Scott Smith – Global Head, Inflammation and Immunology

Patrick Flanigan – Vice President, Investor Relations

Analysts

Josh Schimmer – Piper Jaffray

Geoffrey Porges – Sanford Bernstein

Terence Flynn – Goldman Sachs

Ian Somaiya – Nomura

Robyn Karnauskas – Deutsche Bank

Yaron Werber – Citi

Geoff Meacham – JP Morgan

Ravi Mehrotra – Credit Suisse

Mark Schoenbaum – ISI Group

Brian Abrahams – Wells Fargo Securities

Matt Roden – UBS

Michael Yee- RBC Capital Markets

Mara Goldstein – Cantor Fitzgerald

Thomas Wei – Jefferies

Howard Liang – Leerink Swann

Operator

Good morning and welcome to the Celgene Second Quarter 2014 Earnings conference call. All participants will be in a listen-only mode until the question and answer session at the end of the conference. I would like to remind you that this call is being recorded.

I would now like to turn the conference over to Patrick Flanigan, Vice President, Investor Relations at Celgene. Please go ahead.

Patrick Flanigan – Vice President, Investor Relations

Thanks, Nicole, and welcome everyone to our second quarter earnings conference call. The press release reporting our financial results in addition to the presentation for today’s webcast can be accessed by going to the Investor Relations section of the corporate website at www.celgene.com.

Joining me in the room today with prepared remarks are Bob Hugin, our Chairman and Chief Executive Officer; Jacquie Fouse, our Chief Financial Officer; Mark Alles, who is Global Head of our Hematology and Oncology franchise; and the Global Head of our Inflammation and Immunology franchise, Scott Smith.

As a reminder, during today’s call we will be making forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent 10-Q on file with the SEC. These statements speak only as of today’s date and we undertake no duty to update or revise them. Finally, a reconciliation of the adjusted financial measures to the most comparable GAAP measures are available as part of the earnings release.

Pages: First |1 | ... | Next → | Last | View Full Transcript